Company intelligence / Profile preview
Sylentis
Madrid, Spainsylentis.com ↗
- Ownership
- Private
- Employees
- ~16
- Development stage
- Other
01
Overview
Sylentis has advanced its lead candidate tivanisiran to Phase III clinical trials for dry eye disease. Another candidate, SYL1801 targeting neovascular AMD, is in Phase II. The company has demonstrated promising preclinical and clinical results using its proprietary RNAi technology to silence disease-causing genes primarily in ophthalmology. It also participates in the IPCEI Med4Cure initiative to develop sustainable oligonucleotide manufacturing and therapies targeting rare diseases.[1][4][5]
- Therapeutic areas
- OphthalmologyRare Diseases
- Modalities
- siRNA (small interfering RNA)Oligonucleotide-based drugs
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
IPCEI Med4Cure consortium partners via the SYOLIGO project; additional CDMO partnerships possible but not specified by name.[5]
Beyond the preview
Go deeper on Sylentis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sylentis.